Skip to main content

Table 2 Discounted base case results

From: Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective

Technologies Total Incremental ICER (£)
Add-on to MET Costs (£) LYs QALYs Costs (£) LYs QALYs Incremental cost per QALY gained
DPP-4i £13,593 14.80 11.83 - - - -
Dapagliflozin £13,809 14.80 11.86 +£216 0.01 +0.032 £6,761
  1. Abbreviations: LYs, life years; QALYs, quality-adjusted life years; ICER incremental cost-effectiveness ratio